entertainment -WSS

entertainment

author：explore 2025-09-07 11:14:29 - browse：1653

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Nobel honors Karikó and Weissman's enduring partnership

WSS

Medicare Advantage proposed rates disappoint insurers

Industry veterans launch new biotech VC with $310M

Stop Congress from blocking public access to science

WHO recommends second malaria vaccine

Stop Congress from blocking public access to science

The Karikó problem: Lessons for funding basic research

explore

entertainment

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare threatens to cut off funding for HCA's Mission hospital

Duchenne breakthrough therapy leaves behind pioneering families

Medicare innovation center doesn’t save money, experts say

Apple is now the first public company to be valued at $3 trillion

Medicare threatens to cut off funding for HCA's Mission hospital

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What we’ve learned from the Aduhelm mess

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The United States is paying nearly triple for new Covid vaccines

entertainment

2023 Nobel Prize in Medicine goes to Karikó and Weissman

A disappointing year of Humira biosimilars

The stability of $0 premiums in Medicare Advantage

Industry veterans launch new biotech VC with $310M

Flu, Covid vaccination rates decline, new survey data show

The stability of $0 premiums in Medicare Advantage

focus

leisure time

hotspot

explore